CERO Therapeutics Holdings, Inc. announced on April 22, 2025, that it has entered into a securities purchase agreement for a new convertible preferred stock transaction. This Series D financing is expected to raise up to $8 million in gross proceeds for the company.
The financing structure includes an initial $5 million expected to be received at the first closing, with an additional $3 million that may be funded at one or more subsequent closings, at the election of the investors. This capital infusion is critical for CERO Therapeutics' ongoing operations.
The company intends to use the net proceeds to advance its two recently FDA IND-allowed programs in liquid and solid tumors, complete site activation at MD Anderson Cancer Center, and bring other clinical sites online quickly. The funds will also help address current Nasdaq deficiencies related to Shareholders' Equity and extend the company's cash runway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.